Loading clinical trials...
Loading clinical trials...
68Ga-PSMA PET/CT or PET/MRI in the Evaluation of Patients With Prostate Cancer: A Feasibility Study
This clinical trial studies gallium-68 (68Ga)-prostate specific membrane antigen (PSMA) (gallium Ga 68-labeled PSMA ligand Glu-urea-Lys\[Ahx\]) positron emission tomography (PET)/computed tomography (CT) or PET/magnetic resonance imaging (MRI) in identifying prostate cancer that may have returned after a period of improvement (biochemical recurrence). 68Ga-PSMA is a radiopharmaceutical that localizes to a specific prostate cancer receptor, which can then be imaged by the PET/CT or PET/MRI scanner.
PRIMARY OBJECTIVES: Evaluate the feasibility and biodistribution of 68Ga-PSMA. OUTLINE: Patients are injected with 5 mCi of Ga68 PSMA intravenously (IV) and then undergo PET/CT or PET/MRI approximately 45 to 60 minutes later. After completion of study, patients are followed up at 24 hours and 1 week.
Age
18 - No limit years
Sex
MALE
Healthy Volunteers
No
Stanford University, School of Medicine
Palo Alto, California, United States
Start Date
June 1, 2015
Primary Completion Date
August 1, 2015
Completion Date
August 1, 2016
Last Updated
March 20, 2018
10
ACTUAL participants
Computed Tomography
PROCEDURE
Gallium Ga 68-labeled PSMA Ligand Glu-urea-Lys(Ahx)
DRUG
Magnetic Resonance Imaging
PROCEDURE
Positron Emission Tomography
PROCEDURE
Lead Sponsor
Stanford University
Collaborators
NCT04550494
NCT04857502
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions